Breakfast Consumption and Its Effects on Glycemic, Insulinemic and Non-Esterified Fatty Acids Responses

Glycemic Response Clinical Trial

— BEGIN  

Official title:

Breakfast Consumption and Its Effects on Glycemic, Insulinemic and Non-Esterified Fatty Acids Responses

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03257059
• Other study ID #: 2017/00537
• Status: Completed
• Phase: N/A
• Start date: July 25, 2017
• Est. completion date: March 28, 2019

Study information

• Verified date: May 2019
• Source: Clinical Nutrition Research Centre, Singapore
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to determine whether eating breakfast or having no breakfast has subsequent beneficial health effects, specifically in relation to glycemic response throughout the day and postprandial insulin and non-esterified fatty acids (NEFA) responses 6 hours after breakfast/lunch.

Description:

This will be a randomised, crossover study with two treatments in total. 1.) Subjects given with breakfast, 2.) Subjects not given breakfast. Each of the two test visits will last for approximately 9 hour (spanning over 3 days), during which the following will take place: On Day 1, subjects will come to have the continuous glucose monitoring (CGMS) system inserted. CGMS will be used to measure 24 hour blood glucose concentrations. On Day 2, an indwelling catheter will be inserted into the ante cubital fossa or forearm vein of one arm and will be kept patent. One fasting blood sample (baseline; 4 milliliters of venous blood) will be collected. Participants with breakfast treatment will then consume the test meal within 15 minutes. Subsequently, blood samples will be taken at 15, 30, 45, 60, 90, 120, 150 and 180 minutes.At time 180 minutes, participants will be given a standardized lunch to be consumed within 30 minutes. Blood samples will be taken after lunch at 210, 240, 270, 300, 330 and 360 minutes. On Day 3, subjects will need to come for removal of the CGMS sensor. Subjects will come to the CNRC again for the 2nd test visit, with at least 3 days wash-out in-between visits.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13
• Est. completion date: March 28, 2019
• Est. primary completion date: March 28, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 40 Years to 65 Years

Eligibility

Inclusion Criteria:

• Chinese males

• BMI above 23.0 kg/m2

• Age between 40-65 years

• Normal blood pressure (<140/90 mmHg)

• Fasting blood glucose of =5.6 mmol/L

• Self-reported regular breakfast consumers

Exclusion Criteria:

• Have known glucose-6-phosphate dehydrogenase (G6PD) deficiency

• major chronic disease such as heart disease, cancer or diabetes mellitus

• taking insulin or drugs known to affect glucose metabolism

• Intentionally restrict food intake

• major medical or surgical event requiring hospitalization within the preceding 3 months

• Have taken antibiotics for 3 months before the study period

• Smoking

• Overnight shift workers

• Any known food allergy (eg. anaphylaxis to peanuts)

• Having active Tuberculosis (TB) or currently receiving treatment for TB

• Any known Chronic infection or known to suffer from or have previously suffered from or is a carrier of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV)

• Being a member of the research team or their immediate family members. Immediate family member is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.

• Enrolled in a concurrent research study judged not to be scientifically or medically compatible with the study of the CNRC.

Related Conditions & MeSH terms

• Glycemic Response

Intervention

Other:
• Breakfast
Glutinous rice (75 grams of available carbohydrate)
• No Breakfast
No food to be served in the morning

Locations

Country	Name	City	State
Singapore	Clinical Nutrition Research Centre	Singapore

Sponsors (2)

Lead Sponsor	Collaborator
JeyaKumar Henry	General Mills Inc.

Country where clinical trial is conducted

Singapore, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Glycemic response	Using continuous glucose monitoring system	1.5 days
Primary	Insulin response	Postprandial after treatment	6 hours
Primary	Non-esterified fatty acids (NEFA) response	Postprandial after treatment	6 hours